In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Results from the ESC’s first randomised trial shows education for healthcare professionals can improve guideline implementation

Atrial Fibrillation

Key take-aways 

  • Guideline recommendations support healthcare professionals to provide optimal care; however, they are often poorly implemented. 
  • In the STEEER-AF trial, the first randomised controlled trial conducted by the European Society of Cardiology (ESC), adherence to recommendations in patients with atrial fibrillation (AF) was found to be low across six European countries. 
  • A short educational programme for healthcare professionals increased patient-level adherence to guideline recommendations on heart rhythm control. 
  • Increased efforts are needed to improve guideline implementation and to optimise the care of patients with AF, to prevent the high rate of adverse outcomes. 

 

London, United Kingdom – 1 September 2024: Adherence to atrial fibrillation (AF) guideline recommendations was found to be poor in clinical practice across Europe, but a structured educational programme for healthcare professionals improved implementation of heart rhythm control recommendations in patients, according to late-breaking research presented in a Hot Line session today at the ESC Congress 2024.1 

Explaining why the research was conducted, Chief Investigator, Professor Dipak Kotecha from the University of Birmingham, UK, said: “While guidelines, such as those from the ESC, aim to support healthcare professionals in applying optimal care, their recommendations are often not implemented in clinical practice, with education of healthcare staff identified as a major barrier. We conducted STEEER-AF, the ESC’s first randomised controlled trial,2 with the European Heart Rhythm Association (EHRA) and the ESC Council on Stroke, to test whether a structured educational programme for healthcare professionals could improve guideline-adherent provision of AF care across Europe. We found that adherence to guideline recommendations for heart rhythm control was low, but there were improvements using a short and targeted educational intervention for healthcare staff.” 

STEEER-AF was a cluster randomised trial conducted in France, Germany, Italy, Poland, Spain and the UK. Treatment centres, rather than individuals, were randomised to one of two groups. In centres randomised to the intervention group, healthcare professionals received an additional structured education programme over 16 weeks, which targeted stroke prevention, rhythm control and integrated care, with learning supported by expert local trainers.2 The intervention was developed by ESC Education, EHRA, external content leads and an independent medical education agency. Healthcare professionals spent an average of 9.2 hours on the online learning platform. In centres randomised to the control group, healthcare professionals received only their existing educational activities. 

The co-primary endpoints were adherence to ESC Class I and III recommendations, at the level of each individual patient, for stroke prevention and rhythm control, re-evaluated 6–9 months after randomisation using objective methods at each centre.  

In total, 1,732 patients with AF were studied from 70 randomised centres. The mean age was 69 years, 37% were women and the mean CHA2DS2-VASc score was 3.2, consistent with a real-world population. 

There was no significant improvement in guideline adherence for stroke prevention, which changed from 63.4% to 67.5% in the intervention group and from 58.6% to 60.9% in the control group (adjusted risk ratio [RR] 1.10; 95% confidence interval [CI] 0.97–1.24; p=0.13). 

Significant 51% improvement was observed in guideline adherence for rhythm control, which increased from 21.4% to 33.9% in the intervention group and from 20.5% to 22.9% in the control group (adjusted RR 1.51; 95% CI 1.04–2.18; p=0.03). 

There was also a significant improvement in the patient-reported secondary outcome that evaluated eight domains of integrated AF management, which improved to 77.0% with the intervention and to 71.0% in the control group (baseline-adjusted 5.1% improvement; 95% CI 1.4 to 8.9; p=0.01). 

“The STEEER-AF trial demonstrates that targeted education for healthcare professionals can improve patient-level guideline adherence where there are substantial gaps in implementation, as clearly demonstrated for rhythm control in AF. Overall, the care of AF was poorly adherent to prior guideline recommendations, requiring a total re-think of how guidelines are constructed, disseminated and implemented. As a result of STEEER-AF, the new 2024 ESC Guidelines for the management of AF3,4 incorporate numerous approaches to enhance ‘AF-CARE’, with new patient pathways designed to make implementing recommendations easier and more consistent. In addition, we have simultaneously launched a patient version5 of the 2024 AF Guidelines, to empower patients and encourage a shared-care approach with multidisciplinary healthcare staff,” concluded Professor Kotecha. 

ENDS 

Notes to editor

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2024. It does not necessarily reflect the opinion of the European Society of Cardiology. 

 

ESC Press Office
Tel: +33 (0)6 61 40 18 84  
Email: press@escardio.org

The hashtag for ESC Congress 2024 is #ESCCongress 

Follow us on X @ESCardioNews  

Journalists are invited to become accredited and register here

Check out the ESC Media and Embargo Policy

 

Funding:  STEEER-AF (Stroke prevention and rhythm control Treatment: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomized trial in patients with Atrial Fibrillation) was funded by the European Society of Cardiology and European Heart Rhythm Association, and supported by educational grants from Boehringer Ingelheim, BMS/Pfizer Alliance, Bayer, Daiichi Sankyo and Boston Scientific. Additional funding was provided by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (Oxford, UK) and the Birmingham British Heart Foundation Accelerator (Birmingham, UK).  Trial staff at the coordinating academic centre were supported by the NIHR Birmingham Biomedical Research Centre (Birmingham, UK).  The opinions expressed in this paper are those of the authors and do not represent any of the listed organisations. 

Disclosures: Dipak Kotecha reports grants from the National Institute for Health & Care Research, British Heart Foundation, European Union/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative, European Union Horizon and UK Research and Innovation, UK National Health Service—Data for R&D, UK Department for Business, Bayer, Amomed and Protherics Medicines Development; all outside the submitted work. 

 

References and notes 

1‘STEEER-AF - Stroke prevention and rhythm control therapy’ will be discussed during Hot Line 6 on Sunday 1 September in room London. 

2Sterliński M, Bunting KV, Boriani G, et al., Kotecha D; STEEER-AF Trial Team. Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: A cluster-randomised trial by the European Society of Cardiology and European Heart Rhythm Association. Europace. 2024:euae178; https://doi.org/10.1093/europace/euae178.  

3The 2024 ESC Guidelines for the Management of Atrial Fibrillation will be presented on Sunday 1 September at 13.45 to 15.00 BST in room London:  

4Van Gelder IC, Rienstra M, Bunting KV, et al., Kotecha D. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176; released on 30 August 2024. 

5ESC Guidelines for Patients. Available at: escardio.org/Guidelines/guidelines-for-patients; released on 30 August 2024. 

 

About ESC Congress 2024 

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in London and online – from 30 August to 2 September. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org. 

About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.